The legal action, titled Basma v. GeneDx Holdings Corp., alleges that the company and its executives withheld material information from shareholders throughout the class period. The conflict centers on the company’s acquisition of Fabric Genomics, an AI-driven genomic firm previously marketed as a key driver for scalable revenue and market expansion. Instead of delivering on these projections, the company reported a $31.2 million impairment loss tied to the acquisition.

The fiscal fallout became apparent on May 4, 2026, when GeneDx released first-quarter results for the 2026 fiscal year. Beyond the impairment charge, the firm disclosed that adjusted gross margins had slipped from 74% to 69% and announced that both exome and genome revenue lines failed to meet internal estimates. Consequently, management slashed its full-year revenue guidance from a range of $540–$550 million down to $475–$490 million. The market reaction was swift, with shares plummeting $33.42—a 49.2% decline—in a single session.

Kahn Swick & Foti, LLC, the firm representing the plaintiffs, is currently soliciting investors who suffered substantial losses to participate in the litigation. Managing Partner Lewis Kahn is overseeing the intake process for potential lead plaintiffs, with the court-mandated filing deadline set for early August.